Head-to-head · WeighScore
Luma Health Co vs Obu Health
The verdict
Luma Health Co takes it — 75/100 to 59.9/100.
Luma Health Co grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Luma Health Co is a nurse-practitioner-led virtual weight-loss and wellness clinic founded by Tiffani McKnight, FNP-C.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Luma Health Co | Obu Health |
|---|---|---|
| WeighScore | 75/100 | 59.9/100 |
| Grade | C | C |
| Scorecard rank | #59 | #332 |
| Semaglutide | $120/mo (plus a separate fee, compounded) | $190/mo (starting dose, plus a separate fee, compounded) |
| Tirzepatide | $180/mo (compounded) | $239/mo (starting dose, plus a separate fee, compounded) |
| Coverage | 30 states | Coverage not published |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Graded #59 · C
Strengths
- Transparent, competitive pricing published up front — compounded semaglutide from $120/mo, tirzepatide from $180/mo, retatrutide from $170/mo
- No subscription, monthly fee or membership — a direct-to-patient model where you pay per medication, and follow-up visits are free
- Free initial consults for first responders, law enforcement, military, nurses and teachers ($0), and $25 for other healthcare workers
- Founded and led by a named family nurse practitioner (Tiffani McKnight, FNP-C) licensed across 30 states/DC, with HIPAA-compliant virtual visits
- HSA/FSA funds and financing accepted, with itemized invoices for HSA/FSA submission
Where it loses points
- Offers compounded retatrutide (labeled "RTT/GLP-3"), an investigational triple agonist not FDA-approved — a higher-risk, less-studied option
- Compounded medications only — no brand-name Wegovy, Zepbound or Ozempic — and compounded GLP-1s aren't FDA-reviewed or approved
- No LegitScript certification shown and no compounding-pharmacy partner named, so the dispensing pharmacy can't be independently verified
- Small, newly established founder-led practice with a thin website and limited public track record or third-party reviews
- Medication prices are "starting at" and billed on top of a one-time consult fee, so the true first-month cost runs higher than the headline
Graded #332 · C
Strengths
- LegitScript-certified with publicly displayed ID (44206977)
- Two named 503A compounding-pharmacy partners (Manifest Pharmacy SC + RX Compounding Store FL) — transparency above category baseline
- Lower advertised semaglutide starting price ($190) than most multi-product peer platforms
- Multi-product offering (GLP-1s + NAD+ + sermorelin + generic ED + birth control) for single-platform users
- 24-hour US board-certified physician response window
Where it loses points
- Per-dose pricing tiers not transparently published on product pages — only 'starting from' prices visible
- No explicit state-coverage list disclosed; FAQ confirms restrictions exist 'based on state' without enumeration
- Medical director not named publicly
- No published consultation fee disclosure — unclear whether physician visit is included in medication price
- All sales final per FAQ ('Federal and State law do not allow medication returns')
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.